title: Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
abstract: For more than 50 years, vitamin K antagonists (VKAs) have been the standard of care for treatment of atrial fibrillation (AF). However, the numerous limitations of VKAs have led to the development of non-VKA oral anticoagulants (NOACs). There are 4 NOACs currently approved for prevention of thromboembolism in patients with nonvalvular AF. This article provides an overview of AF, summarizes basic properties of NOACs, and reviews the landmark trials. Current data on use of NOACs in special populations and specific clinical scenarios are also presented. Lastly, recommendations from experts on controversial topics of bleeding management and reversal are described.
authors.affiliation: Department of Internal Medicine, Mount Sinai Hospital, One Gustave L. Levy Place, New York, NY 10029-6574, USA.
authors.forename: Anna
authors.initials: A
authors.lastname: Plitt
authors.affiliation: Cardiovascular Division, TIMI Study Group, Brigham and Women's Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA.
authors.forename: Christian T
authors.initials: CT
authors.lastname: Ruff
authors.affiliation: Cardiovascular Division, TIMI Study Group, Brigham and Women's Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA. Electronic address: rgiugliano@partners.org.
authors.forename: Robert P
authors.initials: RP
authors.lastname: Giugliano
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000097:blood / Q000188:drug therapy*; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D013923:Thromboembolism / Q000097:blood / Q000517:prevention & control*; D014812:Vitamin K
chemical_list: D000925:Anticoagulants; D014812:Vitamin K
keywords: Apixaban; Atrial fibrillation; Dabigatran; Edoxaban; NOAC; Rivaroxaban